
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Urology
Study Phase : Phase II
Recipient : Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Antihistamines on Ureteral Stent-Related Symptoms
Details : Fexofenadine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Nephrolithiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2021
Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Urology
Highest Development Status : Phase II
Recipient : Columbia University
Deal Size : Inapplicable
Deal Type : Inapplicable
